Press release from Companies
Published: 2024-09-26 09:33:00
The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB's ("PHI" or the "Company") preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.
In connection with the Company's preferential rights issue of units carried out in the Spring of 2022, 1,346,162 warrants of series TO 4 were issued. Holders of TO 4 have the right to subscribe for one (1) new share in PHI at a price of SEK 4.63 per share during the exercise period, which runs until 3 October 2024.
In order for warrants not to expire without value, the holder is required to subscribe for new shares, by exercising warrants, no later than 17:00 on 3 October 2024, or sell warrants no later than on 1 October 2024.
An information brochure about the Company and the offer is available on the respective websites of PHI (www.phiab.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Complete terms and instructions for warrants of series TO 4 are available on the Company's website.
In connection with the warrant exercise, PHI has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.
For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se
For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
